Autosomal dominant polycystic kidney disease: the changing face of clinical management
Files
Publication date
2015
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Autosomal dominant polycystic kidney disease is the most common inherited kidney disease and accounts for 7-10% of all patients on renal replacement therapy worldwide. Although first reported 500 years ago, this disorder is still regarded as untreatable and its pathogenesis is poorly understood despite much study. During the past 40 years, however, remarkable advances have transformed our understanding of how the disease develops and have led to rapid changes in diagnosis, prognosis, and treatment, especially during the past decade. This Review will summarise the key findings, highlight recent developments, and look ahead to the changes in clinical practice that will likely arise from the adoption of a new management framework for this major kidney disease.
Keywords
Adolescent, Adult, Aged, Child, Cyclic AMP, Female, Forecasting, Genetic Testing, Humans, Male, Middle Aged, Mutation, Polycystic Kidney, Autosomal Dominant, Prognosis, Protein-Serine-Threonine Kinases, Signal Transduction, TOR Serine-Threonine Kinases, TRPP Cation Channels, Young Adult, Taverne
Citation
Ong, A C M, Devuyst, O, Knebelmann, B, Walz, G, ERA-EDTA Working Group for Inherited Kidney Diseases & Knoers, VVAM 2015, 'Autosomal dominant polycystic kidney disease : the changing face of clinical management', The Lancet, vol. 385, no. 9981, pp. 1993-2002. https://doi.org/10.1016/S0140-6736(15)60907-2